Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Explore the efficacy of radiotherapy combined with Tislelizumab and irinotecan in MSS/pMMR
inoperable recurrent and metastatic colorectal cancer patients; To evaluate the safety and
tolerability of radiotherapy combined with Tislelizumab and irinotecan in MSS/pMMR inoperable
recurrent and metastatic colorectal cancer; To evaluate the radiosensitization effects of
Tslelizumab and irinotecan;